Scienture Holdings shares jump 18.31% intraday on revenue surge and expanded market access for key products.

Scienture Holdings surged 18.31% intraday following the release of its FY earnings report and related business updates. Despite reporting a GAAP EPS loss of $2.70, the company posted a 207.1% year-over-year revenue increase to $0.43 million, driven by the successful commercial launch of Arbli in Q3 2025 and the expanding market access through PBM and GPO agreements. Additionally, the company announced plans to launch REZENOPY in Q2 2026 and confirmed a significantly improved balance sheet with $7 million in cash. These developments, particularly the revenue surge and expansion of institutional access, generated optimism about future growth and strategic momentum, driving the intraday price increase.